Novartis bid to repurpose rare disease drug for cancer falls short in third trial

Novartis bid to repurpose rare disease drug for cancer falls short in third trial

Source: 
BioPharma Dive
snippet: 

A yearslong effort by Novartis to repurpose a rare disease drug for cancer has come up short in a late-stage trial for a third time, closing off an opportunity for the Swiss pharmaceutical company to seek an expanded approval.